Dapagliflozin inhibits selective sodium-glucose co-transporter-2 and Linagliptin competitively and reversibly inhibits dipeptidyl peptidase-4 in fixed dose Combination (1:1) is used in the treatment of Type 2 Diabetes Mellitus.For estimation Dapagliflozin and Linagliptin in bulk and Tablet formulation, an accurate and precise method using RP-HPLC was developed and validated.In the method being discussed here was optimized using Hypersil C18 (250 × 4.6 mm, 5 µm) column as Stationary Phase, Mobile Phase being used is Acetonitrile: Water (90:10) adjusting pH 3 using Ammonium Acetate.The Flow Rate was adjusted to 1mL/min.Both Dapagliflozin and Linagliptin (1:1) sample was detected at analytical wavelength of 244nm using Photo diode array detector.The Linearity Range was between Concentration of 0.1µg/mL to 20µg/mL with correlation Coefficient of 0.995 and 0.999 for Dapagliflozin and Linagliptin Respectively.
No takes yet. Share an insight, caveat, or question.
Chhalotiya et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: